Korean J Gastroenterol.  2005 Oct;46(4):297-301.

A Case of Refractory Pediatric Crohn's Disease with a Successful Treatment by Infliximab Therapy

• Park SH
• Jeen YT
• Chun HR
• Kim DI
• Baeck CW
• Kim YS
• Chun HJ
• Lee HS
• Um SH
• Choi JH
• Kim CD
• Ryu HS
• Hyun JH

Abstract

Crohn's disease is a chronic inflammatory bowel disease which affects mainly children and young adults, and its cause remains unknown so far. Infliximab, a monoclonal antibody to the pivotal cytokine tumor necrosis factor-alpha, has been approved as a drug for both induction and maintenance therapy for moderately to severely active, or fistula-complicated Crohn's disease. The authors report a 12-year-old male patient diagnosed as Crohn's disease complicated with a perianal fistula, which was refractory to the conventional therapy. After the 0, 2, and 6 week scheduled intravenous infusion of infliximab, the patient reached to clinical remission in both subjective symptoms and objective manifestations. For children or young adults who develop Crohn's disease in a refractory course, infliximab may serve as a drug which leads to a clinical improvement or even to an extent of remission.

Keyword

Crohn's disease; Pediatrics; Infliximab

MeSH Terms

Antibodies, Monoclonal/*administration & dosage
Child
Crohn Disease/*drug therapy
Drug Administration Schedule
English Abstract
Gastrointestinal Agents/*administration & dosage
Humans
Infusions, Intravenous
Male